Latest Biopharmaceuticals News

Page 1 of 15
Pfizer has lifted its 2026 revenue and adjusted earnings guidance after a quarter in which newer and acquired medicines grew strongly enough to offset steep declines in COVID-19 products. Overall revenue was flat, while reported net income fell 8%.
Victor Sage
Victor Sage
4 Nov 2026
Vertex has raised its full-year 2026 revenue guidance after third-quarter sales climbed 12%, but the Crinetics acquisition sharply increased costs and debt. The next major test arrives on 30 November, when US regulators are due to rule on povetacicept for IgA nephropathy.
Ada Torres
Ada Torres
3 Nov 2026
Noxopharm has halted trading in its securities while it prepares an announcement about a capital raising. The suspension is scheduled to last until the earlier of the announcement or the start of trading on 2 November 2026, unless ASX decides otherwise.
Ada Torres
Ada Torres
29 Oct 2026
Paradigm Biopharmaceuticals has secured court approval to delay its second creditors meeting until 27 January 2027, giving administrators more time to resolve outstanding matters. The meeting and administrators’ report could still arrive earlier, potentially within weeks.
Victor Sage
Victor Sage
28 Oct 2026
Argent BioPharma ended the September quarter with just A$11,000 in cash after A$734,000 of operating outflows, despite retaining A$7.4 million of unused convertible financing capacity. The company is simultaneously expanding its commercial portfolio through NLC antiviral rights and a CannEpil veterinary programme.
Victor Sage
Victor Sage
23 Oct 2026
CSL has appointed ViiV Healthcare CEO Deborah Waterhouse to lead the biopharmaceutical group from 1 February 2027. Her arrival comes with a substantial UK-pound-denominated remuneration package and a mandate to renew the pipeline while simplifying operations.
Ada Torres
Ada Torres
21 Oct 2026
Avecho Biotechnology has told the ASX it is unaware of any undisclosed information that could explain a sharp move in its share price and a significant increase in trading volume. The company also confirmed compliance with continuous disclosure rules after responding to an exchange price query.
Ada Torres
Ada Torres
21 Oct 2026
Paradigm Biopharmaceuticals has entered voluntary administration after its pivotal Phase 3 trial produced an interim efficacy result below the threshold required for continuation. The company’s securities will remain suspended while administrators assess its viability, liabilities and possible restructuring options.
Ada Torres
Ada Torres
30 Sept 2026
Argent BioPharma has secured exclusive commercialisation rights to selected Tollovir, Tollovid and NutraVir antiviral products in a worldwide deal excluding China. The agreement adds a new commercial pillar alongside CimetrA®, but does not itself grant pharmaceutical development rights or establish clinical efficacy.
Victor Sage
Victor Sage
29 Sept 2026
Clinuvel Pharmaceuticals marked its tenth consecutive profit with stable revenues and rising cash reserves, while accelerating U.S. expansion including a Nasdaq uplisting and potential ASX delisting.
Victor Sage
Victor Sage
27 Aug 2026
Neuren Pharmaceuticals reported an 8% rise in H1 2026 revenues driven by DAYBUE royalties, but profit fell 68% due to ramped-up R&D. The company declared its first ever dividend, signalling confidence amid ongoing clinical and regulatory milestones.
Ada Torres
Ada Torres
26 Aug 2026
Radiopharm Theranostics has dosed the first patient in the second cohort of its Phase 1/2a trial for RV-01, a radiopharmaceutical targeting B7-H3 expressing solid tumors, marking a key dose escalation milestone.
Ada Torres
Ada Torres
26 Aug 2026

Browse the archive

Full archive